GlassScriptPhysician profile
Angela M Wellman
NPI 1225526841
$540.24
in general payments reported to CMS, 2019-2025
12 companies · $60.27 in 2025
The $60.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $14.34 · 2023: $152 · 2024: $15.91 · 2025: $60.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192 · Education: $35.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.16 |
| Education | $35.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $111.58 | 2021 | |
| Amgen INC. | $107.71 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Janssen Biotech, INC. | $94.22 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $71.09 | 2021-2023 | Monjuvi |
| Jazz Pharmaceuticals INC. | $31.08 | 2021 | |
| Gilead Sciences, INC. | $29.20 | 2021-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Immunitybio, INC. | $15.91 | 2024 | |
| Novo Nordisk INC | $15.50 | 2023 | Rybelsus |
| Eisai INC. | $14.79 | 2023 | |
| Taiho Oncology, INC. | $14.77 | 2023 | |
| Merck Sharp & Dohme LLC | $13.39 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Wellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.